Organogenesis Inc. (ORGO)
NASDAQ: ORGO
· Real-Time Price · USD
3.33
0.10 (3.10%)
At close: Jun 23, 2025, 3:59 PM
3.36
1.05%
Pre-market: Jun 24, 2025, 07:06 AM EDT
3.10% (1D)
| Bid | 3.34 |
| Market Cap | 421.79M |
| Revenue (ttm) | 458.76M |
| Net Income (ttm) | -18.63M |
| EPS (ttm) | -0.16 |
| PE Ratio (ttm) | -20.78 |
| Forward PE | 16.12 |
| Analyst | Hold |
| Ask | 3.41 |
| Volume | 590,327 |
| Avg. Volume (20D) | 1,450,132 |
| Open | 3.19 |
| Previous Close | 3.23 |
| Day's Range | 3.13 - 3.34 |
| 52-Week Range | 2.28 - 6.71 |
| Beta | 1.64 |
About ORGO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ORGO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ORGO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Organogenesis Inc. is scheduled to release its earnings on Aug 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-42.7%
Organogenesis Holdings shares are trading lower af...
Unlock content with
Pro Subscription
3 months ago
+19.25%
Organogenesis shares are trading higher after Morgan Stanley raised its price on the stock from $4 to $6.
2 weeks ago · seekingalpha.com
Organogenesis Holdings: ReNu And New LCD Offer A Rebound ScenarioORGO's main drivers are its advanced wound-care and surgical biologics that leverage its evidence-rich portfolio. They have a Phase 3 trial on ReNu knee-osteoarthritis with data anticipated by Septemb...
1 month ago · seekingalpha.com
Organogenesis Holdings Inc. (ORGO) Q1 2025 Earnings Call TranscriptOrganogenesis Holdings Inc. (NASDAQ:ORGO ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer David Francisco - Chief ...
